Adagene Inc   (ADAG)
Other Ticker:  
Price: $2.7000 $0.10 3.846%
Day's High: $2.72 Week Perf: -9.7 %
Day's Low: $ 2.60 30 Day Perf: -4.59 %
Volume (M): 6 52 Wk High: $ 4.38
Volume (M$): $ 16 52 Wk Avg: $1.92
Open: $2.60 52 Wk Low: $1.10

 Market Capitalization (Millions $) 148
 Shares Outstanding (Millions) 55
 Employees -
 Revenues (TTM) (Millions $) 18
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) -34
 Capital Exp. (TTM) (Millions $) 0

Adagene Inc

   Company Address: 4F, Building C14, No. 218 Suzhou 215123 CA
   Company Phone Number: 87773616   Stock Exchange / Ticker: NASDAQ ADAG
   ADAG is expected to report next financial results on April 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Adagene Inc

Adagene Inc Surpasses Expectations with Outstanding Financial Results in Q4 2023

Adagene Inc's financial results for the October to December 31, 2023 fiscal interval show a significant improvement compared to the previous year. The company reported a narrower loss of $-0.35 per share, compared to $-1.48 a year ago. This indicates that the company has been able to reduce its deficit per share, which is a positive sign for investors.
In addition, Adagene Inc saw a substantial increase in revenue, with a 94.9% rise to $18.11 million from $9.29 million in the same period last year. This growth in revenue is a promising sign for the company's future financial performance.

Product Service News

Adagene's Clinical Collaboration Program Shows Promise in Treating Metastatic Colorectal Cancer

Published Fri, Feb 9 2024 11:00 AM UTC

Adagene, a leading biotechnology company, recently announced the progress and expansion of its clinical collaboration program for their promising drug, ADG126 (also known as muzastotug), in combination with KEYTRUDA (pembrolizumab), targeting patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC). This collaboration aims to further demonstrate the effic...

Clinical Study

Unveiling the Potential of ADG126: A New Era for MSS Colorectal Cancer Immunotherapy

Published Tue, Jan 16 2024 10:01 PM UTC

The treatment landscape for metastatic microsatellite-stable (MSS) colorectal cancer (CRC) has been evolving rapidly, with immunotherapy playing a significant role. In a recent study, Adagene presented interim results highlighting the potential of their novel therapy, masked anti-CTLA-4 SAFEbody ADG126 (muzastotug), in combination with pembrolizumab. This article aims to pro...


Adagene Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Adagene Inc does not provide revenue guidance.

Earnings Outlook
Adagene Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com